

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



VOLUNTARY ANNOUNCEMENT

IN RELATION TO THE APPLICATION FOR COMPULSORY ENFORCEMENT BY A WHOLLY-OWNED SUBSIDIARY IN RESPECT OF THE SHAREHOLDERS' RIGHT TO INFORMATION OF BEIJING KANGCHEN BIOLOGICAL TECHNOLOGY CO., LIMITED

This announcement is made by China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide shareholders and potential investors with the latest progress regarding the dispute over the shareholders’ right to information between NT Pharma Pacific Company Limited (“**NT Pacific**”), a wholly-owned subsidiary of the Company, and Beijing Kangchen Biological Technology Co., Limited (北京康辰生物科技有限公司) (“**Kangchen Biological**”).

I. BACKGROUND

NT Pacific currently holds approximately 25.3% equity interest in Kangchen Biological, with the remaining equity interest mainly held by Beijing Konruns Pharmaceutical Co., Ltd. (a company listed on the Shanghai Stock Exchange, stock code: 603590, together with its related parties, collectively referred to as the “**Konruns Parties**”). Kangchen Biological is principally engaged in the pharmaceutical business of “Miacalcic®” and others in the PRC.

The Group and the Konruns Parties completed the acquisition of the relevant interests in “Miacalcic” between 2020 and 2023 (the “**Transaction**”). The Transaction was subject to performance guarantee terms for the period from 2021 to 2023, and all relevant performance undertakings were fully fulfilled. However, upon expiry of the performance guarantee period, the Konruns Parties have, since 2024, unilaterally taken over the operation and management of Kangchen Biological, amended its articles of association, and continuously deprived and obstructed NT Pacific from exercising its right to information as a shareholder and its right to participate in decision-making in accordance with the law, thereby rendering NT Pacific unable to ascertain the true financial position of Kangchen Biological.

The Company is particularly concerned that, while depriving NT Pacific of its shareholders' rights, the Konruns Parties have separately commenced arbitration and made substantial claims against the relevant parties of the Group in respect of arrangements related to the Transaction, and have successively proposed major matters including asset spin-off, shareholder loans or liquidation. In view of the significant deterioration in the operational and financial conditions of Kangchen Biological since 2024, NT Pacific's lawful exercise of its right to information as a shareholder to verify the authenticity of the relevant financial data is well-founded in fact and duly justified.

II. LITIGATION ON SHAREHOLDERS' RIGHT TO INFORMATION AND ENFORCEMENT

NT Pacific has initiated litigation regarding the shareholders' right to information with the People's Court of Changping District, Beijing (the "**Changping Court**") in accordance with the law. On 23 January 2026, the Changping Court rendered the first-instance judgment (2025) Jing 0114 Min Chu No. 38855 ((2025)京0114民初38855號一審判決), ordering Kangchen Biological to maintain materials including its articles of association, resolutions of the general meetings and the board of directors, financial and accounting reports, accounting books and accounting vouchers since its inception at a designated location for inspection and reproduction by NT Pacific or professionals engaged by it. Following an appeal by Kangchen Biological, the Beijing No. 4 Intermediate People's Court rendered the second-instance judgment (2026) Jing 04 Min Zhong No. 409 ((2026)京04民終409號二審判決) on 28 April 2026, dismissing the appeal and upholding the original judgment (collectively, the "**Effective Judgments**"). The second-instance judgment is a final judgment and takes effect from the date of its issuance, explicitly holding that NT Pacific conducted its inspection without any improper purpose and was entitled to engage intermediary institutions to conduct the inspection on its behalf.

Upon the rendering of the Effective Judgments, NT Pacific repeatedly demanded Kangchen Biological to cooperate with the inspection pursuant to the judgments. However, Kangchen Biological disregarded the effective judgments of the People's Court, refused to provide any materials within the statutory performance period, and maliciously obstructed and delayed the process on various unjustified grounds, which has constituted non-performance of effective legal documents. In order to safeguard legitimate rights and interests and uphold the dignity of the law, NT Pacific has applied to the Changping Court for enforcement in accordance with the law and the case has been accepted and docketed under enforcement case number (2026) Jing 0114 Zhi No. 9573 ((2026)京0114執9573號). The Changping Court will adopt statutory compulsory enforcement measures in accordance with the law, including ordering performance within a specified time limit, imposing fines, detention, and pursuing criminal liabilities.

III. THE COMPANY'S POSITION

The Company hereby declares that the Group will unswervingly safeguard its legitimate rights and interests through all lawful means (including but not limited to continuing to advance the enforcement procedures, defending against the arbitration and claims asserted by the Konruns Parties in accordance with the law and initiating all appropriate legal proceedings, as well as pursuing the legal liabilities of the relevant responsible persons), and will under no circumstances tolerate any conduct that flouts the authority of the law or infringes upon shareholders' rights and interests.

IV. IMPACT ON THE COMPANY AND RISK WARNING

The Company will continue to assess the impact of the above matters on the Group in accordance with the requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), and will make further announcement(s) as and when appropriate. The Group's daily operations are maintained in a normal state. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman and Executive Director

Hong Kong, 25 September 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Directors are Dr. Qian Wei, Ms. Chin Yu and Mr. Lou Yongbin; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Kwok Che Chung and Dr. Zhao Yubiao.